Teaching an Old Drug New Tricks: Dexamethasone as an In Vivo Inhibitor of Glioblastoma Dispersal

Unlocking the Glioblastoma Enigma: Exploring PD-L1 (Programmed Death-Ligand 1) and IDH1 (Isocitrate Dehydrogenase-1) Expression and Their Immunotherapeutic Implications

Objective In order to establish a connection between programmed death-ligand 1 (PD-L1) expression and glioma grades as well as the presence of IDH1 mutations, it is necessary to investigate the expression of PD-L1 and isocitrate dehydrogenase-1 (IDH1) in glioma patients and assess their potential as predictive markers for glioblastoma multiforme (GBM) immunotherapy. We analyzed the frequency of PD-L1 expression in glioma samples. Methodology In this two-year retrospective study, 45 glioma cases of varying grades (grades 2 to 4) were examined at a tertiary care hospital. Tumor samples that were formalin-fixed, paraffin-embedded (FFPE) were obtained from the pathology archives of the hospital. According to the WHO Classification of Central Nervous System Tumors, 5th edition, tumor grading and histopathological subtyping were carried out. PD-L1 antibody (clone 28-8) and IDH1 (R132H, clone QM002, Quartett Immunodiagnostika, 1:100 dilution) markers were used for immunohistochemistry (IHC). The sections underwent deparaffinization, rehydration, and antigen retrieval using Leica bond III staining platform. Based on the tumor proportion score (TPS), which is the proportion of viable tumor cells with membranous staining, PD-L1 expression was assessed. The literature's standardized cut-off values were used to determine positive expression. Staining intensity and tumor cell location were used to determine the status of IDH1 mutations. Age, sex, and tumor location were among the clinical and demographic information gathered about the patient. The association between PD-L1 expression, glioma grades, and IDH1 (R132H) mutation status was assessed statistically using SPSS software and a Chi-square test. The threshold for statistical significance was p < 0.05. For every IHC run, positive and negative controls were used as part of the quality control procedures. To reduce bias and guarantee consistency, two pathologists and post graduate residents independently reviewed the results. Results PD-L1 expression was found in 27 out of 36 (75%) grade 4 glioblastoma multiforme cases and six out of nine (66.7%) grade 2 gliomas. Overall, 33/45 (73.3%) of the gliomas had PD-L1 expression. However, PD-L1 expression and glioma grade did not correlate in a statistically significant way. IDH1 (R132H) expression and PD-L1 were found to be inversely correlated (p < 0.05). Conclusion The findings suggest that PD-L1 may be a promising therapeutic target, even in the absence of significant grade-specific trends by demonstrating PD-L1 presence in the majority of glioma cases, highlighting its potential as a therapeutic target in GBM immunotherapy. The results provide insight into the immune landscape of gliomas and pave the way for future research into effective combination therapies for GBM, despite the lack of a significant correlation between glioma grade and PD-L1 expression.